DeepMed Research

Cinacalcet

Generic Name: Cinacalcet

Brand Names: Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₂F_₃N

CAS Number: 226256-56-0

Unique Ingredient Identifier: UAZ6V7728S

Background: Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

Indication: For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Associated Conditions: Hypercalcemia, Secondary Hyperparathyroidism (SHPT)

Clinical Trials

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Phase 3

Completed

Conditions: Secondary Hyperparathyroidism
Chronic Kidney Disease

Interventions: Drug: Cinacalcet
Drug: Etelcalcetide
Drug: Intravenous Placebo
Drug: Oral Placebo

First Posted Date: 2013-07-11

Last Posted Date: 2019-07-18

Lead Sponsor: Amgen

Target Recruit Count: 683

Registration Number: NCT01896232

Locations: 🇹🇷
Research Site, Izmir, Turkey

Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects

Phase 2

Completed

Conditions: Memory Functions

Interventions: Drug: Cinacalcet
Drug: Placebo

First Posted Date: 2012-05-16

Last Posted Date: 2012-10-03

Lead Sponsor: Prof. Dominique de Quervain, MD

Target Recruit Count: 40

Registration Number: NCT01599962

Locations: 🇨🇭
University of Basel, Division of Cognitive Neuroscience, Basel, Switzerland

Interaction Between a Calcimimetic Agent and the Renin Angiotensine Aldosterone System

Not Applicable

Completed

Conditions: Relationship Between Calcimimetic and the RAAS

Interventions: Drug: Cinacalcet 60 MG
Drug: Placebo oral tablet

First Posted Date: 2012-01-26

Last Posted Date: 2020-03-05

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 18

Registration Number: NCT01519037

Locations: 🇨🇭
CHUV, service de néphrologie/hypertension, Lausanne, Vaud, Switzerland

Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)

Phase 2

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: Cinacalcet HCl

First Posted Date: 2011-11-24

Last Posted Date: 2011-11-24

Lead Sponsor: ENRICO VERRINA

Target Recruit Count: 30

Registration Number: NCT01479088

Locations: 🇮🇹
U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini, Genoa, Italy
🇮🇹
U.O. Nefrologia e Dialisi - Ospedale Santobono, Naples, Italy
🇮🇹
U.O. Nefrologia e Dialisi- Ospedale Giovanni XXIII, Bari, Italy

and more 2 locations

An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism

Phase 3

Completed

Conditions: Parathyroid Carcinoma
Hypercalcemia
Primary Hyperparathyroidism

Interventions: Drug: Cinacalcet HCl

First Posted Date: 2011-10-26

Last Posted Date: 2017-03-03

Lead Sponsor: Kyowa Kirin Co., Ltd.

Registration Number: NCT01460030

Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients

Phase 4

Completed

Conditions: Kidney Failure
Secondary Hyperparathyroidism
Vascular Diseases

Interventions: Procedure: Surgical total parathyroidectomy with forearm autografting
Drug: Cinacalcet

First Posted Date: 2011-10-06

Last Posted Date: 2021-10-12

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 67

Registration Number: NCT01447368

Locations: 🇭🇰
Queen Mary Hospital and Tung Wah Hospital, Hong Kong, Hong Kong

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

Phase 2

Terminated

Conditions: Hyperparathyroidism, Secondary
Chronic Kidney Disease

Interventions: Drug: Cinacalcet hydrochloride
Drug: Standard of Care

First Posted Date: 2011-09-23

Last Posted Date: 2020-06-17

Lead Sponsor: Amgen

Target Recruit Count: 18

Registration Number: NCT01439867

Locations: 🇸🇰
Research Site, Kosice, Slovakia

Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease

Phase 1

Completed

Conditions: Chronic Kidney Disease
Hyperparathyroidism, Secondary
Secondary Hyperparathyroidism

Interventions: Drug: Cinacalcet

First Posted Date: 2011-02-04

Last Posted Date: 2020-06-17

Lead Sponsor: Amgen

Target Recruit Count: 14

Registration Number: NCT01290029

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

Pediatric Chronic Kidney Disease Safety and Efficacy

Phase 3

Terminated

Conditions: Chronic Kidney Disease
Kidney Disease
Secondary Hyperparathyroidism
Hyperparathyroidism, Secondary
Hyperparathyroidism

Interventions: Drug: cinacalcet capsule
Drug: placebo
Drug: Standard of Care

First Posted Date: 2011-01-17

Last Posted Date: 2020-06-29

Lead Sponsor: Amgen

Target Recruit Count: 43

Registration Number: NCT01277510

Locations: 🇪🇸
Research Site, Madrid, Spain

Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients

Phase 4

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: Cinacalcet

First Posted Date: 2010-11-30

Last Posted Date: 2014-04-07

Lead Sponsor: Laval University

Target Recruit Count: 23

Registration Number: NCT01250405

Locations: 🇨🇦
Karine Marquis, Québec, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy